AZN

AstraZeneca’s Enhertu recommended for EU approval in HER2-positive solid tumours

AstraZeneca and Daiichi Sankyo’s Enhertu has received a positive CHMP opinion for adults with previously treated unresectable or metastatic HER2-positive solid tumours who have no satisfactory..

AstraZeneca PLC (AZN) Stock Analysis: Strong Buy Ratings and a 20% Upside Potential

AstraZeneca PLC (NASDAQ: AZN), a prominent player in the healthcare sector, stands as a titan among global drug manufacturers. With a market capitalization of $290.06 billion,..

AstraZeneca PLC (AZN) Stock Analysis: Strong Buy Ratings and 23.63% Potential Upside

AstraZeneca PLC (AZN), a leading biopharmaceutical company headquartered in Cambridge, UK, continues to captivate investor interest with its robust pipeline of prescription medicines and strategic collaborations...

AstraZeneca and Daiichi Sankyo secure FDA approval for Enhertu in early breast cancer

The FDA has approved AstraZeneca and Daiichi Sankyo’s Enhertu for both neoadjuvant and adjuvant treatment of HER2-positive early breast cancer, based on results from the Phase..

AstraZeneca PLC (AZN): Investor Outlook Reveals 22.39% Upside Potential and Strong Buy Ratings

AstraZeneca PLC (AZN) continues to draw investors’ attention with its robust position in the healthcare sector, specifically within the drug manufacturing industry. Based in the United..

AstraZeneca PLC (AZN) Stock Analysis: Unpacking a 21% Potential Upside Opportunity

AstraZeneca PLC (AZN), a leading player in the biopharmaceutical sector, continues to capture investor attention with its robust market presence and a significant potential upside. This..

AstraZeneca PLC (AZN) Stock Analysis: Strong Buy Ratings and 11.51% Potential Upside

AstraZeneca PLC (AZN), a leading biopharmaceutical company based in the United Kingdom, remains a compelling choice for investors seeking exposure to the healthcare sector. With a..

FDA approves AstraZeneca’s Saphnelo Pen for self-administration in SLE

AstraZeneca’s Saphnelo has received US approval as a once-weekly autoinjector for adults with systemic lupus erythematosus, offering a self-administered alternative to IV infusion...

AstraZeneca PLC (AZN) Stock Analysis: Eyeing Modest Upside Amid Strong Buy Ratings

AstraZeneca PLC (NASDAQ: AZN), a titan in the healthcare sector and a prominent player among general drug manufacturers, continues to garner significant investor interest. With a..

Third positive Phase III trial supports AstraZeneca’s tozorakimab in COPD

High-level data from the MIRANDA study showed AstraZeneca’s IL-33-targeting biologic tozorakimab significantly lowered annualised moderate-to-severe COPD exacerbations and was generally well tolerated...

AstraZeneca PLC (AZN) Stock Analysis: Navigating Growth and a Strategic Edge in Healthcare

AstraZeneca PLC (NASDAQ: AZN), a leading entity in the healthcare sector, is making waves with its robust market position and strategic advancements in the biopharmaceutical industry...

AstraZeneca PLC (AZN) Stock Analysis: Navigating Growth with a $315 Billion Market Cap and Promising Analyst Ratings

AstraZeneca PLC (AZN), a key player in the global healthcare sector, continues to capture investor attention with its robust market presence and expansive pharmaceutical portfolio. With..

AstraZeneca reports positive Phase III EMERALD-3 results in unresectable liver cancer

In the Phase III EMERALD-3 trial, AstraZeneca’s Imfinzi- and Imjudo-based regimen plus lenvatinib and TACE significantly improved progression-free survival versus TACE alone in embolisation-eligible unresectable hepatocellular..

AstraZeneca PLC (AZN) Stock Analysis: Navigating Potential 10.68% Upside Amid Strategic Growth

AstraZeneca PLC (AZN), a leading player in the global healthcare sector, presents an intriguing investment opportunity for those looking to navigate the dynamic world of pharmaceuticals...

AstraZeneca PLC (AZN) Stock Analysis: Evaluating Growth Potential Amid a 13.53% Upside

AstraZeneca PLC (NASDAQ: AZN), a leading player in the healthcare sector, is drawing investor attention with a market capitalization of $284.63 billion and a strong presence..

AstraZeneca PLC (AZN) Stock Analysis: Navigating a 1.86% Potential Upside Amidst Strong Analyst Ratings

AstraZeneca PLC (NYSE: AZN), a global leader in the biopharmaceutical realm, continues to capture investor attention with its robust portfolio and promising financial outlook. With a..

EU approves AstraZeneca’s Imfinzi with FLOT chemotherapy for early gastric cancer

AstraZeneca’s immunotherapy Imfinzi has been approved in the EU as part of a perioperative regimen with FLOT chemotherapy for resectable gastric and gastroesophageal junction cancers, supported..

AstraZeneca PLC (AZN) Stock Analysis: Evaluating Growth Potential with a 22.84% ROE

AstraZeneca PLC (AZN) remains a formidable player in the global healthcare sector, with its expansive portfolio of prescription medicines targeting a wide array of diseases. Based..

AstraZeneca PLC (AZN) Investor Outlook: Evaluating the Healthcare Giant Amidst a -21.01% Potential Downside

As a titan in the healthcare sector, AstraZeneca PLC (NASDAQ: AZN) commands a significant presence with a market capitalization of $323.16 billion. Known for its robust..

AstraZeneca PLC (AZN) Stock Analysis: Navigating a -19.37% Potential Downside Amidst Robust Dividend Yield

AstraZeneca PLC (NASDAQ: AZN), a formidable player in the healthcare sector, commands a notable market capitalization of $316.57 billion. This UK-based biopharmaceutical giant is renowned for..

Search

Funds

AZN

AstraZeneca’s Enhertu recommended for EU approval in HER2-positive solid tumours

AstraZeneca and Daiichi Sankyo’s Enhertu has received a positive CHMP opinion for adults with previously treated unresectable or metastatic HER2-positive solid tumours who have no satisfactory treatment options...

AstraZeneca and Daiichi Sankyo secure FDA approval for Enhertu in early breast cancer

The FDA has approved AstraZeneca and Daiichi Sankyo’s Enhertu for both neoadjuvant and adjuvant treatment of HER2-positive early breast cancer, based on results from the Phase III DESTINY-Breast11 and DESTINY-Breast05 trials...

FDA approves AstraZeneca’s Saphnelo Pen for self-administration in SLE

AstraZeneca’s Saphnelo has received US approval as a once-weekly autoinjector for adults with systemic lupus erythematosus, offering a self-administered alternative to IV infusion...

Third positive Phase III trial supports AstraZeneca’s tozorakimab in COPD

High-level data from the MIRANDA study showed AstraZeneca’s IL-33-targeting biologic tozorakimab significantly lowered annualised moderate-to-severe COPD exacerbations and was generally well tolerated...

AstraZeneca reports positive Phase III EMERALD-3 results in unresectable liver cancer

In the Phase III EMERALD-3 trial, AstraZeneca’s Imfinzi- and Imjudo-based regimen plus lenvatinib and TACE significantly improved progression-free survival versus TACE alone in embolisation-eligible unresectable hepatocellular carcinoma, with an interim trend toward overall survival benefit...

EU approves AstraZeneca’s Imfinzi with FLOT chemotherapy for early gastric cancer

AstraZeneca’s immunotherapy Imfinzi has been approved in the EU as part of a perioperative regimen with FLOT chemotherapy for resectable gastric and gastroesophageal junction cancers, supported by Phase III MATTERHORN trial data demonstrating reduced risk of progression and death...
Search

Funds

AZN

FTSE 100

Funds